| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 22.46 | 18.6% | 117.6% |
| Total Income | 22.46 | 18.6% | 117.6% |
| Expenditure | 23.82 | 16.8% | 142.6% |
| PBT | -1.96 | 22.2% | 492.0% |
| Net Profit | -1.93 | 25.5% | 406.4% |
| OPM | -6.07% | 1.72pp | 11.00pp |
| NPM | -8.58% | 5.08pp | 14.65pp |
| EPS | -0.07 | 30.0% | 450.0% |
Eton Pharmaceuticals Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 7:47 am
Summary
The press release announces Eton Pharmaceuticals' financial results for the third quarter ended September 30, 2025. Further details regarding specific financial figures are not available in the provided text.
Informational and educational content only. Not investment advice.